Conversely, RKIP serves as a molecular checkpoint that not only inhibits pro-tumorigenic signaling but also maintains immune surveillance by preserving antigen presentation, pro-inflammatory cytokine signaling and the activation of anti-tumor CD8 cytotoxic T cells. The gene discussed is CD8A; the disease is neoplasm.